國家衛生研究院 NHRI:Item 3990099045/13112
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 861667      Online Users : 668
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version
    NHRI > NHRI Graduate Student Program > Others > Periodical Articles >  Item 3990099045/13112


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13112


    Title: Effects of urate-lowering therapy on risk of hyperlipidemia in gout by a population-based cohort study and on in vitro hepatic lipogenesis-related gene expression
    Authors: Fang, YJ;Wu, TY;Lin, CL;Su, CY;Li, JR;Chung, YL;Tien, N;Lim, YP
    Contributors: NHRI Graduate Student Program;National Institute of Environmental Health Sciences
    Abstract: Patients with gout are at a higher risk of cardiovascular disease, which is associated with hyperlipidemia. Management of gout in Taiwan is poor, and the association between urate-lowering therapy (ULT) among gout patients and hyperlipidemia is unclear. We conducted a retrospective cohort study using data from the Longitudinal Health Insurance Database (LHID) of Taiwan on new-onset gout patients and a comparison cohort without gout. A Cox proportional hazards model was used to analyze differences in the risk of hyperlipidemia between patients with and without gout after considering related comorbidities. We also examined the ULT medications on the hepatic expression of lipogenesis-related genes. After adjusting for potential confounders, the case group (44,413 patients) was found to have a higher risk of hyperlipidemia than the control cohort (177,652 patients) [adjusted hazards ratio aHR=2.55]. Gout patients without antigout treatment had significantly higher risk of hyperlipidemia than the control cohort (aHR=3.10). Among gout patients receiving ULT, except those receiving probenecid (aHR=0.80), all had significantly lower risk of hyperlipidemia than gout patients without ULT (all aHR<0.90). Using real-time polymerase chain reaction, we found that most of the antigout drugs decreased the expression of hepatic genes related to lipogenesis in differentiated HepaRG cells. These data indicate that these antigout drugs reduce hyperlipidemia in gout patients, partly via the reduction in expression of lipogenesis-related genes, leading to improved blood lipid profiles. We provide evidence of the strong association between gout and hyperlipidemia and highlight the need for appropriate treatment guidelines.
    Date: 2020-11
    Relation: Mediators of Inflammation. 2020 Nov;2020:Article number 8890300.
    Link to: http://dx.doi.org/10.1155/2020/8890300
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0962-9351&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000595823800001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85097058668
    Appears in Collections:[Others] Periodical Articles
    [Others] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    ISI000595823800001.pdf933KbAdobe PDF229View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback